Study to Evaluate the Effect of GWP42003 on Liver Fat Levels in Participants With Fatty Liver Disease

Summary

The purpose of this study is to evaluate the effect of GWP42003 on liver triglyceride (liver fat) in participants with fatty liver disease (FLD).

Timeline

Start

2011-05-03

Primary completion

2012-07-13

Completion

2012-07-13

Outcome

Missed primary endpoint

registry GWP42003 200 mg/Day Dose vs Placebo; p = 0.222; Mean Difference (Final Values) -6.89 (90% CI -16.35 to 2.56); Regression, Linear NCT01284634 ↗

Drugs

Indications